Free shipping on all orders over $ 500

SU9516

Cat. No. M3890
SU9516 Structure
Synonym:

666837-93-0

Size Price Availability Quantity
5mg USD 85  USD85 In stock
10mg USD 132  USD132 In stock
50mg USD 500  USD500 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

SU9516 is a selective cdk2 inhibitor and support the theory that compounds that inhibit cdk2 are viable resources in the development of new antineoplastic agents. SU9516 is 9-fold and 1.8-fold more selective for cdk2 than cdk4 and cdk1, respectively. Treatment with SU9516 (5 μM) inhibited (P ≤ 0.05) both cdk2-specific (27–64%) and cdk4-specific (26–49%) phosphorylation of pRb in SW480 cells at all (24, 48, and 72 h) time points. RKO cells remained blocked in G2-M at 20 h post-serum induction and -addition of SU9516. SU9516 produced a dose-dependent G1 accumulation in EGF-stimulated cells.Treatment with 5 microM SU9516 prevented dissociation of pRb from E2F1 in all cell lines (HT-29>RKO>SW480). Treatment effects were time-dependent, demonstrating greater inhibition at 48 hr versus 24hr in HT-29 cells. Furthermore, E2F species were sequestered in complexes with p107, p130, DP-1, and cyclins A and E. After a 24-hr treatment with 5 microM SU9516, cyclin D1 and cdk2 levels decreased by 10-60%. Exposure of U937 and other leukemia cells to SU9516 concentrations > or =5 microM rapidly (i.e., within 4 h) induced cytochrome c release, Bax mitochondrial translocation, and apoptosis in association with pronounced down-regulation of the antiapoptotic protein Mcl-1.

Protocol (for reference only)
Cell Experiment
Cell lines RKO cells and SW480 cells
Preparation method Seeding RKO cells and SW480 cells in replicates in 96-well plates at 1 × 104 cells/well and allowing to attach overnight. adding SU9516 in concentrations from 0.05 μM to 50.00 μM for 24 h, then washing the cells twice with PBS, and replenishing cells with complete media. Fixing the cells at 0, 4, and 7 days post-drug removal and assaying for protein levels using a modified SRB cytotoxicity assay.Fixing the cells in 10% trichloroacetic acid for 1 h, washing in distilled H2O, and staining in 0.4% SRB/acetic acid for 30 min. Then washing the cells in 0.1% acetic acid, solubilizing in 10 mM Tris (pH 9), and analyzing on a Bio-Rad 360 microplate reader at 595 nm. Repeating all experiments at least three times.
Concentrations ~50 μM
Incubation time 24 hours
Animal Experiment
Animal models
Formulation
Dosages
Administration
Chemical Information
Molecular Weight 241.25
Formula C13H11N3O2
CAS Number 377090-84-1
Solubility (25°C) DMSO 100 mM
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Gao N, et al. Mol Pharmacol. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.

[2] Moshinsky DJ, et al. Biochem Biophys Res Commun. SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2.

[3] Yu B, et al. Biochem Pharmacol. SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells.

[4] Lane ME, et al. Cancer Res. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.

Related CDK Products
PF-07224826

PF-07224826 is a CDK2/4/6 inhibitor.

INCB123667

INCB123667 is a CDK2 inhibitor.

Senexin B

Senexin B is a potent, orally active CDK8/19 inhibitor with Kd values of 140 nM and 80 nM for CDK8 and CDK19, respectively.

Q901

Q901 is a CDK7 inhibitor for tumor-related studies.

NUV-422

NUV-422 is a CDK2/4/6 inhibitor that can be used in studies related to malignant gliomas.

  Catalog
Abmole Inhibitor Catalog




Keywords: SU9516, 666837-93-0 supplier, CDK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.